We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Compugen Ltd | NASDAQ:CGEN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -1.05% | 1.89 | 1.85 | 1.89 | 1.94 | 1.84 | 1.94 | 392,094 | 22:50:31 |
From Jul 2019 to Jul 2024
Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the first quarter ending March 31, 2011.
Dr. Anat Cohen-Dayag, president and CEO, stated, "Compugen continues to advance its Pipeline Program, targeting the development of superior therapeutic products for important unmet medical needs. As previously disclosed, although our underlying predictive discovery infrastructure is broadly applicable for biological therapeutics and molecular diagnostics, our current focus is on monoclonal antibody ("mAb"), protein and peptide therapeutics in the fields of oncology and immunology, including both autoimmune and inflammatory conditions. Currently, there are more than 30 candidates at various stages of evaluation. In addition to our efforts in advancing this early stage therapeutic pipeline, we continue to undertake additional candidate discovery programs to both increase the number of candidates in the Pipeline and replace those that fail. And, to maintain our leadership position in predictive discovery, our research team continues to enhance our unique discovery infrastructure through the development of additional algorithms and platforms."
Martin Gerstel, Compugen’s chairman, added, "As exemplified in our recent press release describing our broad capabilities in the discovery of superior targets for mAb therapy in cancer, and as illustrated by our existing Pipeline Program to be reviewed in today's webcast, we are finding that the ability to systematically address unmet medical needs through the combined utilization of a number of distinct, but mutually supporting methodologies, all of which are predictive based, is proving to be a major competitive advantage for our Company."
As previously stated, our quarterly results are, and will continue to be, subject to substantial fluctuations. No revenues were recorded for the first quarter of 2011 compared with $125,000 for the first quarter of 2010.
The net loss for the most recent quarter was $1.9 million (including a non-cash expense of $379,000 related to stock based compensation), or $0.06 per share, compared with a net loss of $2.7 million (including a non-cash expense of $911,000 related to stock based compensation), or $0.08 per share, for the corresponding quarter of 2010.
Research and development expenses were $1.7 million for the first quarter of 2011 and $1.6 million for the first quarter of 2010 and remain the Company’s largest category of expense. The amount for the first quarter of 2011 is before the deduction of $48,000 of governmental and other grants; no grants were recognized for the first quarter of 2010.
As of March 31, 2011, Compugen had $25.5 million in cash and cash equivalents and short-term bank deposits, compared with $21.8 million as of December 31, 2010. These amounts do not include the market value of the Evogene shares held by the Company.
Conference Call and Webcast Information
The Company will host a live webcast and conference call at 10:00 AM EDT on Wednesday, May 11, 2011 to review first quarter 2011 results and to present a corporate overview and status slide presentation focusing on the Company’s Pipeline Program.
The live webcast can be accessed from Compugen’s website (www.cgen.com) or at this link. The audio portion will also be available via conference call, which can be accessed by dialing 1-888-407-2553 from the US, or +972-3-918-0610 internationally.
The presentation slides will be available under corporate presentations on the financial reports page of the investors section of the Compugen website (www.cgen.com) or at this link. After clicking on the link, please enter your information, and then please select the second option "Web Participant Application". For support, please call +972-3-925-6000.
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-295-2634 from the US or +972-3-925-5928 internationally. The replay will be available through May 14, 2011.
About Compugen
Compugen is a leading drug and diagnostic discovery company providing novel product candidates addressing important unmet therapeutic and diagnostic needs to pharmaceutical, biotech and diagnostic companies under milestone and royalty bearing or other revenue sharing agreements. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts consist of in silico (by computer) hypothesis-driven product candidate prediction and selection followed by in vitro and in vivo experimental validation. Compugen' unique in silico prediction and selection capabilities are based on a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology tools. Industry collaborations may be entered into before product candidate discovery is undertaken pursuant to "discovery on demand" type arrangements, or with respect to existing product candidates, can be initiated prior to, or at the proof of concept stage, or after selected preclinical activities have been undertaken by Compugen. In 2002, Compugen established an affiliate, Evogene Ltd. (www.evogene.com) (TASE:EVGN.TA), to utilize certain of the Company's in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at www.cgen.com.
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may", "expects", "anticipates", "believes", and "intends", and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's annual reports filed with the Securities and Exchange Commission.
COMPUGEN LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except for share and per-share amounts)
Three Months EndedMarch 31
2011
Unaudited
2010
Unaudited
Revenues - 125 Research and development expenses 1,691 1,635 Less: governmental and other grants (48 ) - Research and development expenses, net 1,643 1,635 Marketing and business development expenses 148 188 General and administrative expenses 643 1,020 Total operating expenses * 2,434 2,843 Operating loss (2,434 ) (2,718 ) Financial income (expenses), net 294 (1 ) Other income 240 - Net loss (1,900 ) (2,719 ) Basic and diluted net loss per ordinary share (0.06 ) (0.08 ) Weighted average number of ordinary shares outstanding 34,091,738 33,010,196* Includes stock based compensation
COMPUGEN LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS DATA
(U.S. dollars, in thousands)
March 31,2011Unaudited
December 31,2010Audited
ASSETS Current assets Cash, cash equivalents and short-term bank deposits 25,532 21,824 Restricted cash 99 684 Trade receivables - 21 Accounts receivable and prepaid expenses 840 548 Receivables from funding arrangement - 5,000 Total current assets 26,471 28,077 Long-term investments Investment in Evogene 5,794 6,227 Long-term prepaid expenses 70 64 Severance pay fund 1,535 1,510 Total long-term investments 7,399 7,801 Property and equipment, net 557 580 Total assets 34,427 36,458 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities Accounts payable and accrued expenses 1,596 2,441 Total current liabilities 1,596 2,441 Long-term liabilities Research and development funding arrangement 4,213 4,037 Accrued severance pay 1,699 1,695 Total long-term liabilities 5,912 5,732 Total shareholders’ equity 26,919 28,285 Total liabilities and shareholders’ equity 34,427 36,458
1 Year Compugen Chart |
1 Month Compugen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
